Research Topics
| J McVernonSummaryAffiliation: University of Melbourne Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective studyJodie McVernon
Vaccine and Immunisation Research Group, Murdoch Children s Research Institute and Melbourne School of Population Health, The University of Melbourne, Parkville, Australia
Influenza Other Respi Viruses 5:7-11. 2011..Seroprevalence studies conducted on stored serum collections indicated low levels of antibody to the novel strain in this age group, leading many to recommend priority immunisation of paediatric populations...- Panvax(®): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009Jodie McVernon
Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and Melbourne School of Population Health, The University of Melbourne, Parkville, Victoria 3010, Australia
Expert Rev Vaccines 10:35-43. 2011..This facilitated early licensure and then rapid rollout for population immunization from October 2009. The vaccine's safety profile in the Australian population has been excellent... - Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza responseJodie McVernon
Murdoch Childrens Research Institute and Melbourne School of Population Health, University of Melbourne, Victoria, Australia
Aust N Z J Public Health 34:113-9. 2010..To define optimum use of the national antiviral stockpile during the early phases of the response to pandemic influenza in Australia, to inform the 2008 revision of the Australian Health Management Plan for Pandemic Influenza... - A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlersJodie McVernon
Murdoch Children s Research Institute and Melbourne School of Population Health, The University of Melbourne, Melbourne, Australia
Pediatr Infect Dis J 31:e15-23. 2012..Recent shifts in serogroup dominance in some settings highlight the desirability of polysaccharide-conjugate vaccines with broader meningococcal coverage than serogroup C vaccines in widespread use... 
Sources, perceived usefulness and understanding of information disseminated to families who entered home quarantine during the H1N1 pandemic in Victoria, Australia: a cross-sectional studyAnne M Kavanagh
Centre for Women s Health, Gender and Society, Melbourne School of Population Health, The University of Melbourne, Melbourne, Victoria, Australia
BMC Infect Dis 11:2. 2011..Specifically, we outline their sources of information; the perceived usefulness of each source; and associations between understanding of recommendations and compliance...- Recommendations for and compliance with social restrictions during implementation of school closures in the early phase of the influenza A (H1N1) 2009 outbreak in Melbourne, AustraliaJodie McVernon
Vaccine and Immunisation Research Group, Murdoch Children s Research Institute and Melbourne School of Population Health, University of Melbourne, Australia
BMC Infect Dis 11:257. 2011..Oseltamivir (Tamiflu) was available for treatment or prophylaxis... - Model answers or trivial pursuits? The role of mathematical models in influenza pandemic preparedness planningJ McVernon
Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and School of Population Health, University of Melbourne, Carlton, Vic, Australia
Influenza Other Respi Viruses 1:43-54. 2007..To this end, we encourage researchers to access FluWeb, an on-line influenza database of historical pandemics and outbreaks... - Changes in the epidemiology of epiglottitis following introduction of Haemophilus influenzae type b (Hib) conjugate vaccines in England: a comparison of two data sourcesJ McVernon
Immunisation Department, Health Protection Agency Centre for Infections, Colindale, London, UK
Epidemiol Infect 134:570-2. 2006..The need for a high index of suspicion to allow early diagnosis of this life-threatening clinical presentation is reinforced... - Understanding the impact of Hib conjugate vaccine on transmission, immunity and disease in the United KingdomJ McVernon
Population Biology of Infectious Disease Group, Department of Zoology, University of Oxford, UK
Epidemiol Infect 136:800-12. 2008..The contribution of herd immunity to disease control was reinforced. Possible intervention strategies will be explored in subsequent work... 
Host and environmental factors associated with Hib in England, 1998-2002J McVernon
Immunisation Department, Health Protection Agency Centre for Infections, London, UK
Arch Dis Child 93:670-5. 2008..Declining effectiveness of the UK's Hib vaccine programme was observed between 1998 and 2002...- Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9John D Mathews
Vaccine and Immunisation Research Group, Melbourne School of Population Health, University of Melbourne, 3010, Victoria, Australia
BMC Infect Dis 10:128. 2010..Were they unexposed, or protected by pre-existing cross-immunity in the first wave, by acquired immunity in later waves, or were their infections asymptomatic?.. - Diagnosis and antiviral intervention strategies for mitigating an influenza epidemicRobert Moss
Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and Melbourne School of Population Health, The University of Melbourne, Parkville, Australia
PLoS ONE 6:e14505. 2011..Here we identify optimal delivery strategies for antiviral interventions accounting for logistical constraints, and so determine how to improve a strategy's impact... - Understanding mortality in the 1918-1919 influenza pandemic in England and WalesDora C Pearce
Vaccine and Immunisation Research Group, Melbourne School of Population Health, The University of Melbourne, Parkville, Vic, Australia
Influenza Other Respi Viruses 5:89-98. 2011..The causes of recurrent waves in the 1918-1919 influenza pandemic are not fully understood... - Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugsJames M McCaw
Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and Melbourne School of Population Health, The University of Melbourne, Parkville, Victoria, Australia
PLoS ONE 3:e2362. 2008..We explored factors promoting resistance within a dynamic infection model, and considered ways in which one or two drugs might be distributed to delay the spread of resistant strains or mitigate their impact... - Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccineTerry Nolan
Vaccine and Immunisation Research Group, Murdoch Children s Research Institute and School of Population Health, University of Melbourne, Victoria, Australia
Pediatr Infect Dis J 30:190-6. 2011..Neisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries. A Haemophilus influenzae type b-meningococcal serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) was evaluated... - Comparison of three methods for ascertainment of contact information relevant to respiratory pathogen transmission in encounter networksJames M McCaw
Murdoch Childrens Research Institute, University of Melbourne, Parkville, Vic, Australia
BMC Infect Dis 10:166. 2010..We report on a pilot study designed to assess three different methods (one retrospective, two prospective) for obtaining contact data relevant to the determination of these mixing patterns... - Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and childrenTerry Nolan
Melbourne School of Population Health, The University of Melbourne, Victoria, Australia
Vaccine 26:6383-91. 2008..Our objective was to evaluate the safety and immunogenicity of a prototype inactivated, aluminium adjuvanted, split-virus, clade 1 H5N1 vaccine (A/Vietnam/1194/2004/NIBRG-14) in infants and children aged > or =6 months to < 9 years... - Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trialTerry Nolan
Vaccine and Immunization Research Group, School of Population Health, University of Melbourne, and Murdoch Children s Research Institute, Victoria, Australia
JAMA 303:37-46. 2010..In the ongoing influenza pandemic, a safe and effective vaccine against 2009 influenza A(H1N1) is needed for infants and children... - Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and childrenTerry Nolan
Vaccine and Immunisation Research Group at the Murdoch Children s Research Institute and the Melbourne School of Population Health, University of Melbourne, Victoria 3010, Australia
Influenza Other Respi Viruses 3:315-25. 2009..Our objective was to evaluate the safety, reactogenicity and immunogenicity of a thimerosal-free inactivated influenza vaccine (Fluvax; CSL Limited, Parkville, Australia) in children aged 6 months to <9 years... - Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemicJames M McCaw
Vaccine and Immunisation Research Group, School of Population Health, The University of Melbourne, VIC 3010, Australia
Math Biosci 209:336-60. 2007..In contrast, a treatment based strategy typically does not delay the onset of a pandemic by an appreciable amount and, in general, is not capable of significantly reducing the attack rate from baseline... - Understanding Australia's influenza pandemic policy on the strategic use of the antiviral drug stockpileJames M McCaw
Vaccine and Immunisation Research Group, Melbourne School of Population Health, University of Melbourne and Murdoch Childrens Research Institute, Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Vic, Australia
Med J Aust 191:136-7. 2009..Targeted post-exposure prophylaxis represents a more efficient use of the stockpile than treatment alone... - Likely effectiveness of pharmaceutical and non-pharmaceutical interventions for mitigating influenza virus transmission in MongoliaK J Bolton
Melbourne School of Population Health, University of Melbourne, Carlton, Victoria 3010, Australia
Bull World Health Organ 90:264-71. 2012..To assess the likely benefit of the interventions under consideration for use in Mongolia during future influenza pandemics... - Understanding influenza transmission, immunity and pandemic threatsJohn D Mathews
Melbourne School of Population Health, The University of Melbourne, Melbourne, Australia
Influenza Other Respi Viruses 3:143-9. 2009..Nevertheless, partial protection, even of short duration, induced by prior seasonal influenza or vaccination against it, could provide important protection in the early stages of a new pandemic... - A biological model for influenza transmission: pandemic planning implications of asymptomatic infection and immunityJohn D Mathews
Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and School of Population Health, The University of Melbourne, Parkville, Victoria, Australia
PLoS ONE 2:e1220. 2007..We have modelled multiple wave outbreaks of influenza from different populations to allow for changing immunity and asymptomatic infection and to make inferences about R(0)...